5-hydroxy-8-bromo-3,4-dihydrocarbostyril | 66951-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-hydroxy-8-bromo-3,4-dihydrocarbostyril
• 英文别名: 8-bromo-5-hydroxy-3,4-dihydrocarbostyril；8-bromo-5-hydroxy-3,4-dihydro-1H-quinolin-2-one
• CAS: 66951-89-1
• 化学式: C₉H₈BrNO₂
• 分子量: 242.072
• InChiKey: CUIKMKFHNHPLPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.04
• 重原子数：
  13.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  49.33
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  5-hydroxy-8-bromo-3,4-dihydrocarbostyril 、 1-溴-3-氯丙烷 生成 8-bromo-5-(3-chloropropoxy)-3,4-dihydrocarbostyril
  参考文献：
  名称：

  CAKAHO, KADZUO;FUDZIOKA, TAKAFUMI;OSIRO, YASUO;NAKAGAVA, KADZUYUKI

  摘要：

  DOI：
• 作为产物：
  描述：

  8-bromo-5-acetyloxy-3,4-dihydrocarbostyril 以 8N-hydrochloric acid 为溶剂， 生成 5-hydroxy-8-bromo-3,4-dihydrocarbostyril
  参考文献：
  名称：

  Pharmaceutically useful carbostyril derivatives

  摘要：

  卡波司酯衍生物具有抗组胺作用和中枢神经控制作用，可用作抗组胺剂或中枢神经控制剂。这些衍生物由通式所代表，其中R.sup.1是氢原子、具有1至6个碳原子的烷基基团、具有2至4个碳原子的烯基基团、具有2至4个碳原子的炔基基团或含有1至4个碳原子的烷基基团的苯基基团；R.sup.2是氢原子、具有1至4个碳原子的烷基基团或苯基团；R.sup.3是氢原子、羟基、具有1至4个碳原子的烷基基团、具有1至4个碳原子的烷酰氧基团或3,4,5-三甲氧基苯甲酰氧基团；R.sup.4是氢原子或具有1至4个碳原子的烷基基团；R.sup.5是具有3至8个碳原子的环烷基基团、苯基（可能有1至3个卤素原子、具有1至4个碳原子的烷基基团和具有1至4个碳原子的烷氧基团中选择的取代基）、具有1至4个碳原子的烷基基团（具有一个取代基，如羟基、苯基或具有1至4个碳原子的烷酰氧基团）、具有1至4个碳原子的烷酰基或苯甲酰基；X是卤素原子；n为0或1或2的整数；Q为2或3的整数，l和m分别为0或1至6的整数，但l和m的总和不应超过6；卡波司酯骨架中3-位和4-位的碳-碳键为单键或双键；以及##STR2##的侧链的取代位置为4-、5-、6-、7-或8-位中的任意一个。

  公开号：

  US04734416A1

文献信息

• Novel carbostyril derivatives
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04298739A1

  公开（公告）日：1981-11-03

  Novel carbostyril derivatives having platelet aggregation inhibitory action, antiinflamatory action, antiulcer action, vasodilatory action and phosphodiesterase inhibitory action and are useful for preventing or curing thrombus, arteriosclerosis, hypertension, asthma and other like diseases, and also useful as an antiinflamatory or anti-ulcer agent, represented by the formula ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, phenyl-C.sub.1-4 alkyl-; R.sup.2 is hydrogen, a halogen atom, hydroxy, phenyl-C.sub.1-4 alkoxy; R.sup.3 is hydrogen, hydroxy, C.sub.1-4 alkyl; R.sup.4 is C.sub.3-8 cycloalkyl, substituted or unsubstituted phenyl, C.sub.3-8 cycloalkyl-C.sub.1-4 alkyl, 2-(3,4-dimethoxyphenyl)-ethyl, R.sup.5 is hydrogen, C.sub.1-8 alkyl, C.sub.2-4 alkenyl, phenyl, C.sub.3-8 cycloalkyl, phenyl-C.sub.1-4 alkyl, C.sub.3-8 cycloalkyl-C.sub.1-4 alkyl, m is an integer of 1 - 3, l and n which may be same or different, and are respectively 0 or an integer of 1 - 7 and the sum of l and n is not exceeding 7, the carbon-carbon bond at 3- and 4-positions in the carbostyril skelton is either single or double bond.

  具有抗血小板聚集抑制作用、抗炎作用、抗溃疡作用、扩血管作用和磷酸二酯酶抑制作用的新型羧基吲哚衍生物，用于预防或治疗血栓、动脉硬化、高血压、哮喘等疾病，同时也可用作抗炎或抗溃疡剂，其结构式如下：其中R.sup.1为氢、C.sub.1-4烷基、C.sub.2-4烯基、苯基-C.sub.1-4烷基-；R.sup.2为氢、卤素原子、羟基、苯基-C.sub.1-4烷氧基；R.sup.3为氢、羟基、C.sub.1-4烷基；R.sup.4为C.sub.3-8环烷基、取代或未取代苯基、C.sub.3-8环烷基-C.sub.1-4烷基、2-(3,4-二甲氧基苯基)-乙基；R.sup.5为氢、C.sub.1-8烷基、C.sub.2-4烯基、苯基、C.sub.3-8环烷基、苯基-C.sub.1-4烷基、C.sub.3-8环烷基-C.sub.1-4烷基；m为1-3的整数，l和n可以相同也可以不同，分别为0或1-7的整数，且l和n的和不超过7，在羧基吲哚骨架的3-和4-位置的碳-碳键为单键或双键。
• Carbostyril derivatives, and antihistaminic agents containing the same
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04482560A1

  公开（公告）日：1984-11-13

  Novel carbostyril derivatives and their salts having antihistaminic effects and are useful as antihistaminic agents, represented by the general formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, a lower alkenyl group, a lower alkynyl group or a lower alkyl group which may have phenyl group(s) as the substituted group(s); R.sup.2 is a hydrogen atom, a lower alkyl group or a phenyl group; R.sup.3 is a lower alkyl group having phenyl group(s) as the substituted group(s), or a phenyl group which may have 1 to 3 substituted groups selected from the group consisting of halogen atoms, lower alkyl groups and lower alkoxy groups; R.sup.4 is a hydrogen atom, a hydroxyl group or a lower alkanoyl group; X is a halogen atom; Y is a lower alkylene group which may have hydroxyl group(s) as the substituent(s); n is 0, 1 or 2; the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or double bond; provided that when R.sup.3 is a lower alkyl group having phenyl group(s) as the substituted group(s), then R.sup.4 should be neither a hydroxyl group nor a lower alkanoyl group.

  具有抗组胺效果并可用作抗组胺剂的新型碳基苯并噻唑衍生物及其盐，由通式（1）表示，其中R1为氢原子，较低的烯基基团，较低的炔基基团或较低的烷基基团，其可以具有苯基（作为取代基）;R2为氢原子，较低的烷基基团或苯基;R3为具有苯基（作为取代基）的较低烷基基团，或者是可以具有来自卤素原子，较低烷基基团和较低烷氧基的1至3个取代基的苯基;R4为氢原子，羟基或较低的烷酰基基团;X为卤素原子;Y为较低的烷基烯基基团，其可以具有氢氧基（作为取代基）;n为0，1或2;在碳基苯并噻唑骨架中3-和4-位置之间的碳-碳键为单键或双键;前提是当R3为具有苯基（作为取代基）的较低烷基基团时，R4不应为羟基或较低的烷酰基基团。
• Carbostyril derivatives and pharmaceutical preparations containing same
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04824840A1

  公开（公告）日：1989-04-25

  Carbostyril derivatives having antihistaminic action and central nervous controlling action are useful as antihistaminic agents or central nervous controlling agents. The derivatives are represented by the general formula, ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms or a phenylalkyl group, an alkylene group containing 1 to 4 carbon atoms; R.sup.2 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a phenyl group; R.sup.3 is a hydrogen atom, a hydroxy group, an alkyl group having 1 to 4 carbon atoms, an alkanoyloxy group having 1 to 4 carbon atoms or a 3,4,5-trimethoxybenzoyloxy group; R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R.sup.5 is a cycloalkyl group having 3 to 8 carbon atoms, a phenyl group (which may have 1 to 3 substituted groups selected from the group consisting of halogen atoms, alkyl groups having 1 to 4 carbon atoms and alkoxy groups having 1 to 4 carbon atoms), an alkyl group having 1 to 4 carbon atoms (having one substituted group such as a hydroxy group, a phenyl group or an alkanoyloxy group having 1 to 4 carbon atoms), an alkanoyl group having 1 to 4 carbon atoms or benzoyl group; X is a halogen atom; n is 0, or an integer of 1 or 2; Q is an integer of 2 or 3, l and m are respectively an integer of 0 to 1-6, but the sum of l and m should not exceed 6; the carbon-carbon bond at the 3- and 4-positions in the carbostyril skeleton is a single or double bond and; the substituted position of the side chain of ##STR2## is any one of the 4-, 5-, 6-, 7- or 8-positions.

  羧基苯基吡啶衍生物具有抗组胺作用和中枢神经控制作用，可用作抗组胺剂或中枢神经控制剂。该衍生物由通式## STR1 ##表示，其中R.sup.1是氢原子，具有1至6个碳原子的烷基，具有2至4个碳原子的烯基，具有2至4个碳原子的炔基或苯基烷基，含有1至4个碳原子的烷基，R.sup.2是氢原子，具有1至4个碳原子的烷基或苯基，R.sup.3是氢原子，羟基，具有1至4个碳原子的烷基，具有1至4个碳原子的烷酰氧基或3,4,5-三甲氧基苯甲酰氧基，R.sup.4是氢原子或具有1至4个碳原子的烷基，R.sup.5是具有3至8个碳原子的环烷基，苯基（可能具有1至3个取代基，所述取代基选自卤原子，具有1至4个碳原子的烷基和具有1至4个碳原子的烷氧基），具有1至4个碳原子的烷基（具有一个取代基，例如羟基，苯基或具有1至4个碳原子的烷酰氧基），具有1至4个碳原子的烷酰基或苯甲酰基; X是卤原子; n为0或1或2的整数; Q为2或3的整数，l和m分别为0至1-6的整数，但l和m的总和不应超过6;羧基吡啶骨架中3-和4-位置的碳-碳键是单键或双键; ## STR2 ##的侧链的取代位置是4-，5-，6-，7-或8-位置之一。
• Carbostyril derivatives
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0467325A2

  公开（公告）日：1992-01-22

  Carbostyril derivatives of Formula I: wherein: m is 0, 1, or 2; n is 0, 1, or 2; R1 is hydrogen or lower alkyl; R2 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, aralkoxy, or acyloxy; R3 is hydrogen, halogen, lower alkyl, or lower alkoxy; R4 is hydrogen, hydroxy, lower alkyl, or acyloxy, provided that when R4 is hydroxy or acyloxy, m and n are both 1; R5 is hydrogen or lower alkyl; and R6 is alkyl, hydroxyalkyl, alkoxyalkyl, or (dialkylamino)alkyl; and the pharmaceutically acceptable acid addition salts and N-oxides (at the carbostyril nitrogen) thereof, and compositions containing them, are useful in treating cardiovascular diseases, particularly arrhythmias. Methods of preparing intermediates, the compounds, and their formulations are also disclosed.

  式 I 的喹诺酮衍生物： 其中 m 是 0、1 或 2 n 是 0、1 或 2 R1 是氢或低级烷基 R2 是氢、卤素、羟基、低级烷基、低级烷氧基、芳基氧基或酰氧基； R3 是氢、卤素、低级烷基或低级烷氧基； R4 是氢、羟基、低级烷基或酰氧基、 但当 R4 为羟基或酰氧基时，m 和 n 均为 1； R5 是氢或低级烷基；R6 是烷基、羟基烷基、烷氧基烷基或（二烷基氨基）烷基； 及其药学上可接受的酸加成盐和 N-氧化物（碳氮基），以及含有它们的组合物，可用于治疗心血管疾病，特别是心律失常。还公开了制备中间体、化合物及其制剂的方法。
• BANNO, KAZUO;FUJIOKA, TAKAFUMI;OSHIRO, YASUO;NAKAGAWA, KAZUYUKI
  作者：BANNO, KAZUO、FUJIOKA, TAKAFUMI、OSHIRO, YASUO、NAKAGAWA, KAZUYUKI

  DOI：——

  日期：——